Labcorp Holdings Inc.
LHLabcorp Holdings Inc. (LH) is a leading global life sciences company providing diagnostic, testing, and clinical trial services. Founded in 1978, it offers a broad range of laboratory testing, drug development, and one-health solutions to healthcare providers, pharmaceutical companies, and biopharmaceutical firms. Headquartered in Burlington, North Carolina, Labcorp plays a key role in advancing personalized medicine and improving patient outcomes through its extensive diagnostic and research capabilities.
Dividend History
Investors can expect a dividend payout of $0.72 per share, scheduled to be distributed in 48 days on March 12, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 12, 2026 | $0.72 | 2026-02-27 | 2026-02-27 |
| December 11, 2025 | $0.72 | 2025-11-26 | 2025-11-26 |
| September 11, 2025 | $0.72 | 2025-08-28 | 2025-08-28 |
| June 11, 2025 | $0.72 | 2025-05-29 | 2025-05-29 |
| March 12, 2025 | $0.72 | 2025-02-27 | 2025-02-27 |
Dividends Summary
- Consistent Payer: Labcorp Holdings Inc. has rewarded shareholders with 16 dividend payments over the past 4 years.
- Total Returned Value: Investors who held LH shares during this period received a total of $11.52 per share in dividend income.
- Latest Payout: The most recent dividend of $0.72/share was paid 43 days ago, on December 11, 2025.
- Yield & Schedule: LH currently pays dividends quarterly with an annual yield of 1.07%.
- Dividend Growth: Since 2022, the dividend payout has grown by 0.0%, from $0.72 to $0.72.
- Dividend Reliability: LH has maintained or increased its dividend for 16 consecutive payments.
Company News
Labcorp Holdings Inc. (NYSE:LH) announced a quarterly cash dividend of $0.72 per share, payable on March 12, 2026, to shareholders of record as of February 27, 2026. The company is a global leader in laboratory services with nearly 70,000 employees serving clients in approximately 100 countries.
A consumer analysis examines how Taurus Medical, Inc. operates its telehealth TRT platform, which connects patients with licensed healthcare providers through OpenLoop Healthcare Partners. The analysis details the regulatory framework for testosterone as a Schedule III controlled substance, the three-entity operational structure (platform, provid...
The global autism spectrum disorder diagnostics market is projected to grow from $27.38 billion in 2024 to $43.36 billion by 2034, with a CAGR of 4.7%. Key growth drivers include increasing healthcare expenditure, R&D investments, and government initiatives. The autistic disorder segment will dominate at 52.82% market share, while early intervent...
The global bioanalytical services market is expected to grow from US$ 3.96 billion in 2025 to US$ 11.61 billion by 2035 at a CAGR of 11.6%. Growth is driven by FDA Modernization Act 2.0 implementation, increased clinical trial activity, and a shift toward advanced testing methodologies like cell-based assays and LC-MS/MS platforms. Cell-based ass...
The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. Nort...
